Ad
AMGN Quote Trading Chart Amgen Inc.
home / stock / amgn / amgn quote
$249.51 Last:
-0.88% Change Percent:
$249.07 Open:
$251.72 Previous Close:
$250.67 High:
$247.88 Low:
876,613 Volume:
12/31/1969 07:00:00 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
AMGN Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2022-08-15 | 249.07 | 251.72 | 250.67 | 247.88 | 876,613 |
| 2022-08-12 | 248.52 | 251.72 | 249.85 | 246.3 | 3,460,883 |
| 2022-08-11 | 252.04 | 251.72 | 253.36 | 247.99 | 2,686,696 |
| 2022-08-10 | 249.81 | 251.72 | 252.46 | 248.53 | 2,628,294 |
| 2022-08-09 | 247.21 | 251.72 | 249.72 | 247.21 | 2,061,749 |
| 2022-08-08 | 245 | 251.72 | 247.74 | 244.31 | 2,783,783 |
| 2022-08-05 | 246.46 | 251.72 | 247.08 | 241.79 | 2,723,408 |
| 2022-08-04 | 247 | 251.72 | 249 | 246.2 | 2,647,024 |
| 2022-08-03 | 245.94 | 251.72 | 249.33 | 245.18 | 2,061,298 |
| 2022-08-02 | 246.69 | 251.72 | 247.85 | 243.78 | 2,292,255 |
| 2022-08-01 | 247.34 | 251.72 | 248.16 | 244.651 | 1,957,021 |
| 2022-07-29 | 248.46 | 251.72 | 249.57 | 245.74 | 3,295,633 |
| 2022-07-28 | 251.72 | 251.72 | 251.72 | 245.725 | 2,158,756 |
| 2022-07-26 | 249.63 | 249.63 | 253.07 | 248.75 | 987,714 |
| 2022-07-25 | 246.86 | 248.72 | 249.0937 | 246.56 | 1,771,131 |
| 2022-07-19 | 246.96 | 247.32 | 247.775 | 245.04 | 3,373,901 |
| 2022-07-18 | 248.55 | 243.84 | 249.45 | 242.92 | 2,231,381 |
| 2022-07-15 | 247.39 | 248.69 | 249.13 | 245.441 | 2,805,358 |
| 2022-07-14 | 245.02 | 245.59 | 246.82 | 242.95 | 2,885,765 |
| 2022-07-13 | 246.37 | 247.09 | 248.75 | 245.1601 | 2,498,009 |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022 PR Newswire Phase 1 Tarlatamab Study Showed Encouraging Antitumor Activity With Median Duration of Response of 13 Months in Small Cell Lung Cancer No Approved Treatment Options Available to Patients in Th...
-
AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS PR Newswire First Data From LUMAKRAS Plus Immunotherapy and LUMAKRAS Plus SHP2 Inhibitor Combinations Show Clinical Activity and Su...
-
AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif. , Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2022. Key results include: Total revenues increased ...